Navigation Links
Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
Date:3/16/2008

Phase I/II data showed that Enhanze Technology(TM) enabled subcutaneous administration of a monthly dose of GAMMAGARD LIQUID in patients with

Primary Immunodeficiency

PHILADELPHIA, March 16 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) today announced the preliminary results of a Phase I/II clinical trial, in which subcutaneous infusion (under the skin) of GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] (IGIV) with Enhanze(TM) Technology enabled administration of a full monthly dose via a single site to patients with primary immunodeficiency (PID). The results were presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in Philadelphia, PA.

GAMMAGARD LIQUID is approved for intravenous administration, which due to large infusion volumes of the therapy needing to be delivered, can take several hours once a month at a doctor's office or hospital. By contrast, subcutaneous administration of IGIV has been limited by the inability of the tissue to absorb large volumes of injected drugs, creating the need to administer the therapy in smaller, weekly doses and through multiple injection sites. Subcutaneous administration of GAMMAGARD LIQUID with Enhanze Technology via a single site could allow patients to administer a sufficient dose of IGIV once monthly at home.

In the Phase I/II trial, 10 of the 11 patients studied received monthly doses of subcutaneously administered GAMMAGARD LIQUID with Enhanze Technology of 25.5 to 61.2 grams (255 to 612 mL) in a single site. All patients in the trial received the therapy at infusion rates between 120 mL/hr to 300 mL/hr, similar to infusion rates for intravenous administration. The average bioav
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
2. U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCs DVC and Baxter
3. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
4. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
7. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
8. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
9. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Calif. , May 20, 2013 /PRNewswire-iReach/ -- ... of the first study demonstrating detection of pathogenic ... Yersinia pestis and Bacillus anthracis ... and Prevention,s list of potential bio-threats. This seminal ... and Technology Laboratory, Salisbury ...
(Date:5/20/2013)...  TRACE International today released its Global Enforcement ... against individuals and government or business entities for bribery ... 2012 is the third in an annual series ... "Although the number of outbound enforcement actions fell ... priority," said Alexandra Wrage , TRACE ...
(Date:5/20/2013)... EL SEGUNDO, Calif. , May 20, 2013 /PRNewswire/ ... helped perfect for use both in space and on ... of Fame. The technology assures high ... by compact and low-power ultrasound units, like those used ... ultrasound is already the diagnostic imaging solution of choice ...
Breaking Medicine Technology:Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3Wyle Aided System Gets Named to Space Technology Hall of Fame 2Wyle Aided System Gets Named to Space Technology Hall of Fame 3
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today reported ... effects on pulmonary artery pressure of LEVADEX™, dihydroergotamine mesylate ... there was no statistically significant difference between the LEVADEX ... artery pressure over two hours after administration. LEVADEX is ...
... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader ... company overview at Stifel Nicolaus, 2010 Healthcare Conference on Thursday, ... Seasons Hotel in Boston, MA. A live audio ... & Media" section of the Company,s Web site, www.isispharm.com ...
Cached Medicine Technology:MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial 2MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial 3MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX™ and Placebo in Pharmacodynamics Trial 4
(Date:5/20/2013)... 2013 For the third consecutive ... of Frederick Award in the Professional Standards Review ... , The USCA "Best of Local Business" Award ... Each year, the USCA identifies companies that they ... local community and business category. These are local ...
(Date:5/20/2013)... The new healthcare bill proposes to ... all Americans. However, not all the conditions were to ... might take up to 2014 to show anything. ... states are currently moving forward to implement the health ... Iowa, Michigan, New Hampshire, and West Virginia. HHS will ...
(Date:5/20/2013)... Daily Gossip, online magazine about lifestyle, health and sports ... that can help them overcome one of the most spread ... Natural Vitiligo Treatment System has created a buzz on ... received from the persons who have tried it. Its principles ... interviewed some of the people who tried it and managed ...
(Date:5/20/2013)... People are so busy these days, running ... through the roof and are contributing to a number of ... mean the difference between life and death. Speakers at the ... May will share valuable, practical tools people can use to ... around them for social good. , Organised by V ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 ... Foundation will be holding a ... Lansing on June 10th. , ... 10th, 6:30 p.m. – 8 ... (Across from Sparrow Hospital),                  ...
Breaking Medicine News(10 mins):Health News:A2LA Receives 2013 Best of Frederick Award 2Health News:Review of Health Bill Impact in 2014 2Health News:Review of Health Bill Impact in 2014 3Health News:New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine 2Health News:Chill Out and Change the World, Say Mind Experts at V Star Bliss Event in Sydney 2
... ... system that automatically matches the right clients with the right lenders making the whole ... conversions for retailers. , ... Orlando, FL (PRWEB) June 17, 2009 -- The world of Equipment Leasing/Financing is ...
... ORANGE COUNTY, Calif., June 17 Applied Medical, a ... in the Premier healthcare alliance ,s ... in healthcare while highlighting healthcare industry suppliers committed to ... Innovation Celebration highlights innovative solutions that bring a positive ...
... rescue manager won contest to clone beloved pet Trakr, hero of ... Can you clone a hero? Retired ... dog and 9-11 hero, Trakr, will receive five answers to that ... biotech company that is offering the first commercial dog cloning service ...
... Focus on promoting ... ... signed a Memorandum of Understanding (MOU) to promote healthcare travel in the Pacific Asia region. ... and drive more integration between the travel and healthcare industries., , , , ,Under the ...
... Dr. Bryan Selkin, the ... new state of the art location at 5044 Tennyson in Plano. Dr. Bryan Selkin will ... ... Selkin, the Chief Dermatologist of the Dermatology Center of Plano will be relocating his practice to ...
... Withdraws Two Cold Remedy Nasal Products Citing Commitment to Consumer ... Matrixx Initiatives, Inc. (Nasdaq: MTXX ) has ... U.S. Food and Drug Administration about two of its 19 ... Zicam Cold Remedy Swabs. The warning letter cited consumer reports ...
Cached Medicine News:Health News:The Equipment Leasing/Financing World Now Has its First Exclusive Online Referral Service 2Health News:The Equipment Leasing/Financing World Now Has its First Exclusive Online Referral Service 3Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 2Health News:Applied Medical Selected by the Premier Healthcare Alliance to Highlight Commitment to Healthcare Quality Improvement, Innovation 3Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 2Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 3Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 2Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 3Health News:New State of the Art Dermatology Center in Plano TX 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3
Inquire...
Using proven 1064 nm technology for the treatment of deeper lesions, the Lumenis One Multi-Spot Nd:YAG module provides versatility allowing targeted treatment of leg veins, vascular lesions, facial w...
... provides an ideal treatment for ... such as the great and ... wavelength targets water in the ... means a much more comfortable ...
...
Medicine Products: